Base Editing (BE4max) for COL7A1 c.8045A>G (p.Lys2682Arg) in Dystrophic epidermolysis bullosa (including subcorneal cleavage phenotype)

Base Editing (BE4max) via AAV delivery is a rationale-driven therapeutic strategy for Dystrophic epidermolysis bullosa (including subcorneal cleavage phenotype) targeting the COL7A1 c.8045A>G (p.Lys2682Arg) variant (Pathogenic, missense variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: Skin. Therapeutic goal: Restore functional COL7A1/type VII collagen expression in skin and mucosa (via gene addition or gene editing) to re-establish anchoring fibrils at the dermal–epidermal junction and prevent blistering,. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: COL7A1 NM_000094.4(COL7A1):c.8045A>G (p.Lys2682Arg) is classified as Pathogenic (ClinVar variation ID 3376581). Molecular consequence: missense variant. Protein change: K2682R. 2. Epidemiology: Inherited epidermolysis bullosa overall has a prevalence around 11 per million; DEB subtypes ~3.3 per million, with roughly similar prevalence of dominant and recessive forms. Disease is ultra-rare but present worldwide, with patients concentrated in specialized centers and registries. 3. Standard of care: Supportive wound care (dressings, infection control), pain and pruritus management, nutritional and gastrointestinal support, surgical management of pseudosyndactyly and contractures, and surveillance/treatment of aggressive cutaneous squamous cell carcinoma. Before gene therapies, no disease-modify 4. Pipeline: Two advanced gene/cell therapies are now approved in major markets: topical HSV-1–based COL7A1 gene therapy beremagene geperpavec (B-VEC, Vyjuvek) for DEB wounds and autologous gene-corrected keratinocyte sheet therapy prademagene zamikeracel (ZEVASKYN) for recessive DEB. Multiple Phase I/II trials 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting COL7A1 c.8045A>G (p.Lys2682Arg) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically.
2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed.
3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.